Yes, Keytruda Treats Multiple Cancers
Keytruda (pembrolizumab) is an FDA-approved immunotherapy drug used to treat various cancers. It works as a PD-1 inhibitor, helping the immune system target and destroy cancer cells by blocking proteins that tumors use to evade detection.[1]
Which Cancers Does Keytruda Target?
Keytruda is approved for over 30 indications across solid tumors and blood cancers, including:
- Melanoma (advanced or unresectable).
- Non-small cell lung cancer (NSCLC), often with chemotherapy or as first-line treatment.
- Head and neck squamous cell carcinoma.
- Classical Hodgkin lymphoma.
- Urothelial carcinoma (bladder cancer).
- Microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers, regardless of tumor location.
- Triple-negative breast cancer (in combination therapies).
- And others like renal cell carcinoma, endometrial carcinoma, and esophageal cancer.[1][2]
It's often used when tumors express PD-L1 or have specific biomarkers, but approvals vary by stage, line of therapy, and combination with other drugs.
How Does Keytruda Work?
Keytruda binds to the PD-1 receptor on T-cells, preventing interaction with PD-L1 on cancer cells. This unleashes T-cells to attack tumors. It's administered via IV infusion every 3-6 weeks, with dosing based on body weight (2 mg/kg) or fixed (200-400 mg).[1]
Common Side Effects and Risks
Patients report fatigue, musculoskeletal pain, diarrhea, nausea, and rash. Serious immune-related effects include pneumonitis, colitis, hepatitis, and endocrinopathies, which can be life-threatening and require steroids. Monitoring is essential, especially in combinations.[1][2]
How Does Keytruda Compare to Other Immunotherapies?
| Drug | Mechanism | Key Cancers | Major Difference from Keytruda |
|------|-----------|-------------|-------------------------------|
| Opdivo (nivolumab) | PD-1 inhibitor | NSCLC, melanoma, renal | Similar efficacy; Keytruda often edges in NSCLC survival data [3] |
| Tecentriq (atezolizumab) | PD-L1 inhibitor | NSCLC, bladder | Targets ligand directly; broader combo approvals |
| Imfinzi (durvalumab) | PD-L1 inhibitor | NSCLC, small cell lung | Strong in consolidation after chemoradiation |
Keytruda leads in approvals and sales ($25B+ annually), but competitors challenge in specific settings.[3]
Who Makes Keytruda and What's the Cost?
Merck & Co. manufactures and markets Keytruda. A typical 28-day cycle costs $10,000-$15,000 before insurance or assistance programs. Patient support like Merck's Access Program covers copays for eligible U.S. patients.[1]
When Does Keytruda's Patent Expire?
Core U.S. patents on pembrolizumab expire around 2028, with formulation patents extending to 2035. Challenges from biosimilar makers like Samsung Bioepis and Viatris are ongoing; FDA could approve biosimilars post-2028 if litigation favors generics. Check DrugPatentWatch.com for latest expiry and litigation updates: DrugPatentWatch - Keytruda Patents.4
[1]: FDA Keytruda Label (fda.gov)
[2]: Merck Keytruda Prescribing Information (merck.com)
[3]: NEJM Studies on PD-1 Inhibitors (nejm.org)